Navigation Links
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Date:12/9/2009

with the endoscopy procedures. The most commonly reported SAE following endoscopy was acute pancreatitis requiring hospitalization.

"Although this study did not achieve the pre-specified statistical outcome for the primary endpoint, it provides further evidence of the benefits of RG1068 in MRI imaging of the pancreas," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "Further development plans for RG1068 will be determined following discussion of these results with the FDA next quarter."

This was a multi-center, baseline controlled, single dose study in which 258 patients with a history of pancreatitis at 23 clinical sites within the U.S. and Canada received an MRI of the pancreas with and without RG1068, and independently an endoscopic procedure called ERCP. The MRI imaging results were randomized and independently evaluated by three radiologists blinded to the details of the MRI procedures for evaluation of pancreatic duct abnormalities, image quality, number of duct segments visualized and confidence in diagnosis. The use of MRI is attractive for patient care as it can obviate the need for more risky invasive procedures such as ERCP.

RG1068 is a synthetic version of human secretin, a natural gastrointestinal hormone involved in the process of digestion. Secretin has been used for many years by gastroenterologists in conjunction with ERCP, an invasive procedure to evaluate and treat diseases of the pancreas and gallbladder. There are risks associated with the use of ERCP, which have generated interest in the development of safer non-invasive tests to diagnose gastrointestinal disorders. The use of RG1068 in combination with a non-invasive procedure such as MRI can improve the detection of abnormalities and increase the diagnostic quality of the MRI image of the pancreas. The FDA has granted RG1068 Orphan Drug status and Fast Track Designation, a process designed to facilitate the deve
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
2. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
3. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
4. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
5. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
8. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
9. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
10. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
11. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), a specialty ... innovative therapies for the treatment of acute pain, today ... the three and six months ended June 30, 2015. ... 23, 2015, the Committee for Medicinal Products for Human ... the management of acute moderate-to-severe post-operative pain in adult ...
(Date:8/3/2015)... Aug. 3, 2015 Diplomat Pharmacy, Inc. (NYSE: ... results for the quarter ended June 30, 2015. All comparisons, ... 2014. Second Quarter 2015 Highlights include: ... or $266 million , Total prescriptions dispensed of 234,000, ... versus 5.5% , Adjusted EBITDA of $22.7 million, an ...
(Date:8/3/2015)... , Aug. 3, 2015  LEO Pharma supports ... Administration (FDA) to include psoriasis as one of eight ... Development Initiative i .  Psoriasis is an autoimmune disease ... subsequent comorbidities, affecting 7.5 million people in the US ... Pharma,s ongoing commitment to supporting patients living with psoriasis, ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3
... ALLEGAN, Mich. , Jan. 27 Perrigo ... declared a quarterly dividend of $0.0625 per share, ... record on February 26, 2010 . , Perrigo Company ... distributes over-the-counter (OTC) and generic prescription pharmaceuticals, nutritional products, active ...
... , , , , RALEIGH, ... leading Clinical Research Organization, announces it has entered into a ... company, and its exclusive partner IBPC, a non-profit oncology research ... which collectively treat an estimated 140,000 new incidences of cancer ...
Cached Medicine Technology:PRA International Formalizes Partnership with Oncopartners and IBPC 2PRA International Formalizes Partnership with Oncopartners and IBPC 3PRA International Formalizes Partnership with Oncopartners and IBPC 4PRA International Formalizes Partnership with Oncopartners and IBPC 5
(Date:8/4/2015)... Hanover, MA (PRWEB) , ... August 04, 2015 , ... ... Brain Aneurysm Awareness on Sunday, September 20th at Oneida Shores Park in Brewerton, ... after suffering from a ruptured brain aneurysm at the young age of 59. Her ...
(Date:8/4/2015)... ... August 04, 2015 , ... IN AMERICA and the ... treating depression. Depression affects millions of Americans every single year. To help people ... enlighten viewers with the latest segment produced with the assistance of several top ...
(Date:8/4/2015)... DC (PRWEB) , ... August 04, 2015 , ... Following ... two new videos: The Benefits of Cath Lab Accreditation in an Academic Setting, and ... in an Academic Setting , taped during the 2015 Society for Cardiovascular Angiography ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... make the Isabel Symptom Checker available to all users of the KHIN personal ... check their symptoms in an easy, intuitive method, provides access to material on ...
(Date:8/3/2015)... ... 04, 2015 , ... While the pace of the economic recovery since the 2008 has been ... a growth trajectory for the last six years. Unemployment has dropped from a 2009 high ... 3.5 percent growth rate in 2014, the U.S. stock market is at an all time ...
Breaking Medicine News(10 mins):Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 2Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 3Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 2Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 3Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 2Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 4
... -- A University of Michigan Health System laboratory study reveals ... could lead to a new treatment for those with sickle ... in this week,s early edition of the Proceedings of ... preventing the painful episodes and organ damage that are common ...
... Gordon HealthDay Reporter , TUESDAY, Nov. 1 (HealthDay ... their risk of developing cancer compared to the general population. ... cancer, according to new research. In any ... transplant is just 0.7 percent. And experts say the benefits ...
... Gardner HealthDay Reporter , TUESDAY, Nov. 1 ... disorder don,t appear to raise the risk of heart ... adults, new research shows. And if any ... Concerta does exist, the danger in absolute numbers would ...
... equation that is difficult to solve for most people, but ... transport can be an almost insurmountable task. A newly launched ... now enlisting the help of the senior citizens themselves to ... hoped that the results will lead to better urban planning. ...
... -- Women undergoing angioplasty, a procedure to unblock a clogged ... to new research. However, the study also shows ... an angioplasty than male patients. In conducting the study, ... Interventions , researchers analyzed information on almost 4,800 women and ...
... from Rhode Island Hospital examined how the perception of ... Through a web survey with embedded interventions, the researchers ... indicators of patient satisfaction, while staff reported changing or ... paper was published in the European Journal of ...
Cached Medicine News:Health News:Researchers reveal potential treatment for sickle cell disease 2Health News:Cancer Risk Doubles After Organ Transplant, Study Finds 2Health News:Cancer Risk Doubles After Organ Transplant, Study Finds 3Health News:Little Evidence of Heart Risks From ADHD Meds 2Health News:Little Evidence of Heart Risks From ADHD Meds 3Health News:Little Evidence of Heart Risks From ADHD Meds 4Health News:Senior citizens as co-researchers to improve urban planning 2Health News:Women No More Likely to Die After Angioplasty 2Health News:How staff perceptions of their roles impact patients experience in the emergency department 2Health News:How staff perceptions of their roles impact patients experience in the emergency department 3
... was developed to address hematology needs ... of use, low maintenance, closed-tube sampling, ... are features expected in the modern ... fast access to results, sophisticated data ...
Inquire...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: